AUTHOR CONTRIBUTION FORM

Title	*A Phase II Study of vorinostat and rituximab for treatment of indolent non-Hodgkin lymphoma (newly diagnosed and relapsed/refractory)*
First author	Robert Chen

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html):

"Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship".

The responsible author of this manuscript confirms that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Responsible author *(author responsible for the integrity of the work as a whole)*
Name: Robert Chen
Institute: City of Hope
e-mail: rchen@coh.org

Author contributions *Please describe the contributions of each author, indicating who was responsible for each part of the study and the preparation of the manuscript (collection of data, experiments, data analysis, generation of figures, interpretation of data, preparation of the text, etc.) :*
Contributions: RC, PF, MK contributed to study design and execution; data collection, analysis and interpretation; and manuscript preparation. MM contributed to data collection and study execution. NR contributed to data analysis and manuscript preparation. AR contributed to data collection and data interpretation. ST contributed to data interpretation and manuscript preparation, NN, MH and AN contributed to data interpretation, SJF contributed to study design. All authors approved the final manuscript. The authors report no potential conflicts of interest.